UOBKayHian

技術分析 | 大中華

Friday, 13 November 2026

技術分析

分析師

大中華區研究團隊
research-hk@uobkh.com

譚文漢，特許財務分析師
munhon.tham@uobkh.com
+852 2236 6799



領展房產基金 (0823 HK)

最後價格:	港幣 41.50 元
支撐位:	港幣 39.70 元/港幣 38.60 元
阻力位:	港幣 45.60 元/港幣 47.88 元

技術分析:

价格行为展开了高确信度的结构性突破，自转换后的阻力转支撑基线强劲反弹并收出一根看涨阳线，同时有效突破了旗形趋势延续形态的上方边界。技术动能强力印证了这一突破扩张：RSI 指标牢牢锚定于看涨区间，并以强劲的正向速度向上攀升。只要价格行为在盘中回踩中严格防守在转换后的支撑基线上方，最小阻力路径将高度倾斜于向更高的波段高点阻力区域展开持续的向上拓展。

平均時限：約兩週。



中國生物製藥 (1177 HK)

最後價格:	港幣 5.57 元
支撐位:	港幣 5.26 元/港幣 5.15 元
阻力位:	港幣 6.28 元/港幣 6.59 元

技術分析:

价格行为在突破后展开了高确信度的结构性防守，成功守住了新建缺口支撑区域上方的位置。RSI 指标牢牢锚定于看涨区间，并以正向速度向上攀升。只要价格行为在盘中回踩中严格防守在缺口支撑门槛上方，最小阻力路径将高度倾斜于向更高的波段高点阻力区域展开持续的向上拓展。

平均時限：約兩週。

IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS

This report is provided subject to various disclosures and disclaimers (the "Disclosures / Disclaimers") which form an integral part of this report and are available at this link or by scanning the QR code below:

The Disclosures / Disclaimers contain important information, including without limitation, (a) exclusions of liability, (b) confidentiality obligations, (c) restrictions on publication, circulation, reproduction, distribution and use of the report, (d) potential conflicts of interest, and (e) disclosures and requirements specific to recipients in the United States and other applicable jurisdictions.

Specifically, this report is intended for general circulation and informational purposes only and does not take into account the specific investment objectives, financial situation, or particular needs of any individual person. It is not intended to constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment, taking into account your specific objectives, financial situation and needs, before making any investment decision. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report.

Recipients of this report must carefully read, review and understand the full Disclosures / Disclaimers before using or relying on any information in this report. By accessing, receiving or using this report, you acknowledge and confirm that you have read, understood, accepted and agreed to be bound by the Disclosures / Disclaimers (as may be amended or updated from time to time) in full."